This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teva Reintroduces Generic Depo-Provera Injection in U.S.
by Zacks Equity Research
Teva (TEVA) announced the reintroduction of the generic equivalent to Depo-Prover Contraceptive Injection 150 mg/mL in the United States.
Intercept (ICPT) Provides Safety Guidelines For Ocaliva
by Zacks Equity Research
Intercept Pharmaceuticals, Inc. (ICPT) provided a statement on the recent safety and dosing issues for lead drug Ocaliva and reinforced that the recommended dosing is safe.
AstraZeneca's Bevespi Improves Lung Function in Phase III Study
by Zacks Equity Research
AstraZeneca plc (AZN) announced top-line data from a late stage study, which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with COPD.
3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day
by Arpita Dutt
With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.
Kite Pharma Triples So Far in 2017: What's Driving the Rally?
by Zacks Equity Research
Kite Pharma's (KITE) shares have surged 300% so far this year riding on the progress of its CAR-T therapy candidate and a favorable buyout offer from Gilead.
Roche (RHHBY) Gets Approval for Label Expansion of Tecentriq
by Zacks Equity Research
Roche Holding AG (RHHBY) announced a label expansion of immunotherapy drug Tecentriq for the treatment of non-small cell lung cancer in Europe.
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid
by Zacks Equity Research
Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.
How is the Age-Related Macular Degeneration Space Faring Now?
by Zacks Equity Research
The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
Mylan Down 24% Year to Date: What's Troubling the Stock?
by Zacks Equity Research
Shares of Mylan N.V. (MYL) have declined 24.7% in the last six months compared to the industry's loss of 20%.
Novartis Poised to Grow on Oncology Portfolio & Biosimilars
by Zacks Equity Research
Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah.
Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View
by Zacks Equity Research
Pfizer's (PFE) cancer drug Sutent gets a mixed opinion from an FDA advisory committee regarding a regulatory application, which was filed to expand its label.
Novartis Announces Positive Data on Urticaria Drug Xolair
by Zacks Equity Research
Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA.
Catalyst (CPRX) Focused on Two Lead Pipeline Candidates
by Zacks Equity Research
: Catalyst (CPRX) remains focused on development of its two lead pipeline candidates, Firdapse and CPP-115.
J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU
by Zacks Equity Research
J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.
Biosimilar 2017 Progress Report: Stocks in Focus
by Zacks Equity Research
The biosimilar space remains in the spotlight as a number of regulatory decisions are pending.
Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx
by Zacks Equity Research
Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.
Roche (RHHBY) Announces Data on Respiratory Drug Esbriet
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced results from a six-month study combining idiopathic pulmonary fibrosis (IPF) drug Esbriet (pirfenidone) and Ofev.
Array's NDAs for Melanoma Combo Accepted for Review by FDA
by Zacks Equity Research
Array BioPharma's (ARRY) new drug applications for the combination of binimetinib and encorafenib to treat melanoma, accepted for review by the FDA.
Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA
by Zacks Equity Research
Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG's (RHHBY) Rituxan.
Roche's Ophthalmology Drug Fails to Meet Primary Endpoint
by Zacks Equity Research
Roche's (RHHBY) share price declined after its ophthalmology candidate, lampalizumab, failed to meet the primary endpoint in phase III Spectri study.
Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis
by Swarup Gupta
North Korea-related tensions weighed on stocks across the world last week.
Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus
by Zacks Equity Research
With the approval of Novartis AG' (NVS) Kymriah, investors have started to shift their focus on a number of companies which have been developing their pipeline candidates.
MEI Pharma-Presage Biosciences on License Deal for Voruciclib
by Zacks Equity Research
MEI Pharma (MEIP) signs a license contract with Presage Biosciences to develop its CDK inhibitor, voruciclib, by dint of which, it nabs exclusive rights to the oncology candidate.
Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study
by Zacks Equity Research
Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents.
Ligand (LGND) Diabetes Candidate Positive in Phase II Study
by Zacks Equity Research
Ligand's (LGND) diabetes candidate, LGD-6972, demonstrated a change of statistical significance in blood glucose level (HbA1c) from baseline over a treatment period of 12 weeks.